An internal operations pilot at Labcorp Drug Development is serving as an "Innovation Incubator" to launch new ways of working across its clinical and laboratory service teams to solve important issues that can impact the client and patients during a clinical trial.

AACR 2023 -- Upwards of 50% of cancer patients will receive radiation during the course of their treatment, mostly through a fractionated dosing schedule. Labcorp Drug Development has a wealth of data across syngeneic models employing a single dose of focal radiation.

AACR 2023 -- Colorectal cancer (CRC) is one of the most common cancers with 200,000 U.S. cases per year. Adenocarcinoma is the most common type of CRC, making up 95 percent of all CRC cases. Checkpoint inhibitors used for CRC have shown efficacy for a specific subset of patients.

AACR 2023 -- Establishing long-term CAR T persistence and efficacy remains a barrier to broader application of CAR T therapies in the clinic, thus development of robust platforms that can provide longitudinal assessments of CAR T persistence and functionality is paramount.

AACR 2023 -- The availability of syngeneic models for ovarian cancer is extremely limited. The ID8-luc ovarian model is established intraperitoneally with disease progression resulting in the accumulation of ascites fluid. However, solid tumors do not reliably form, making assessment of immunomodulation challenging.

AACR 2023 -- Clinically lung cancer often metastasizes to the brain, significantly reducing life expectancy. Many patients with non-small cell lung cancer (NSCLC) already have brain metastasis when they are first diagnosed.

AACR 2023 -- Tumor microenvironment (TME) is rich in cells that potentially inhibit T cell function, such as regulatory T cells (Tregs) and myeloid derived suppressor cells (MDSCs).

AACR 2023 -- The prognosis for people with pancreatic cancer is poor, with an average 5-year survival rate of 10% and only 3% for those with metastatic illness. Pancreatic cancer patients have few therapeutic options, and innovative therapies are sorely needed to improve treatment of the disease.

AACR 2023 -- Triple immunodeficient mouse models are often necessary to evaluate xenograft models and adoptive cell therapies using human immune cells. Triple immunodeficient mice lack functional T cells, B cells and natural killer (NK) cells.